Citations

Clear

143 citation(s) found for "Louis, David N".

Longitudinal Detection of Circulating Tumor DNA in Children with Pleuropulmonary Blastoma: A Report from the International PPB/DICER1 Registry
Schultz, Kris Ann P , Field, Amanda L , Mallinger, Paige H R , Xu, Chenyu , Deonovic, Benjamin , Nelson, Alexander T , Watson, Dave , Hagedorn, Kelly , Olson, Damon R , Kamihara, Junne , Chen, Kenneth S , Mitchell, Sarah G , Wilson, David B , Amend, Christina E , Mize, William , Su, Yan , Duan, Chao , Yue, Zhixia , Gao, Chao , Klega, Kelly S. , Dehner, Louis P , Messinger, Yoav H , Crompton, Brian D , Harris, Anne K , Hill, Dana Ashley

Mayo Clinic

Clinical Cancer Research | November 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-1981 | PMID 43043066 Get It

Abstract Purpose: Pleuropulmonary blastoma (PPB) is the most common lung cancer of early childhood. Nearly all PPBs have biallelic DICER1 variants: a loss-of-function allele (often germline) and a second RNase IIIb domain "hotspot" substitution. Except in somatic mosaicism, these hotspots are tumor-specific and ideal liquid biopsy targets. Experimental Design: For individuals with PPB enrolled in the International PPB/DICER1 Registry, blood samples were collected at timepoints coordinated with clinical venous access. Tumor sequencing identified each patient's RNase IIIb hotspot, enabling personalized droplet digital PCR assays to detect that variant in circulating tumor DNA (ctDNA). Results: We analyzed 482 samples from 20 type I and 53 type II/III PPB patients. Among 13 pre-operative type II/III patients sampled pretreatment, 11 (85%) had detectable ctDNA, with tumor size moderately correlated with ctDNA burden (Spearman's ρ=0.574, p=0.051). In contrast, among 8 patients sampled after resection but before chemotherapy, none had detectable ctDNA (p<0.001 vs. unresected). After chemotherapy initiation, ctDNA levels spiked within 1–2 days before rapidly declining. During post-event surveillance, ctDNA was detectable a median of 5.3 weeks before clinical progression (21.7 weeks for negative samples; p=0.001). In type I PPB, DICER1 variants were detectable only in patients with somatic mosaicism. Conclusions: In type II/III PPB, ctDNA correlates with tumor size and resection status. The transient rise and fall in ctDNA following initiation of chemotherapy suggests that ctDNA could serve as a real-time in vivo assay of tumor responsiveness, and these findings support further investigation as a pharmacodynamic biomarker for disease response and recurrence detection.
Isocitrate Dehydrogenase Mutation Assessment in Human Glioma Using Desorption Electrospray Ionization–Multiple Reaction Monitoring
Shahi, Mahdiyeh , Garcia, David M., Quiñones-Hinojosa, Alfredo, Cooks, R. Graham , Cooks, R Graham

Mayo Clinic

Analytical Chemistry | July 21, 2026 | Volume: 98 | Issue: 30 | Pages: 22080-22087

10.1021/acs.analchem.6c00520 | PMID 42477897 Get It

Abstract The mutation status of isocitrate dehydrogenase (IDH) in glioma patients has diagnostic and prognostic significance but is available only after surgery. Rapid and sensitive intraoperative molecular diagnosis is essential for distinguishing tumor from infiltrative and from normal brain tissue to maximize safe resection. IDH-mutant (mut)tumors produce high concentrations of 2-hydroxyglutarate (2HG), which serves as a surrogate marker of IDH mutation. Here, we use desorption electrospray ionization-multiple reaction monitoring (DESI-MRM), a form of mass spectrometry (MS), for rapid prediction of IDH mutation status. A set of 30 human brain smears was analyzed using DESI-MRM experiments to predict the mutation status of IDH and quantify 2HG in glioma samples within 2 min (endogenous reference molecule) or 7 min (external standard). Nanoelectrospray ionization (nESI) was employed as a validation method. An isotopically labeled surrogate internal standard allowed quantitative measurement of 2HG and clear separation between IDH-mut and IDH-wildtype (wt) samples, showing 100% agreement with clinical diagnosis. 2HG concentrations in IDH-mut samples ranged from 88 to 1445 ng mg–1, while IDH-wt samples exhibited 2HG concentrations of 9–15 ng mg–1. Calibration curves showed method accuracy within ≤15%. The quantitative results obtained using isotopically labeled standards showed a strong correlation between IDH mutation score and 2HG concentrations, as did an earlier semiquantitative (ratiometric, endogenous standard) method. These findings highlight the standalone capability of DESI-MRM for making measurements to justify assessments for intraoperative diagnosis and to support surgical decision-making to improve patient outcomes.
Wireless, Battery-Free Implant for Motor Cortex Chronic Stimulation
Benbuk, Abed, Gulick, Daniel, Garcia, Diogo Moniz-, Quinones-Hinojosa, Alfredo, Blain, Jennifer, Benbuk, Ahmed Abed , Gulick, Daniel , Garcia, David M., Quiñones‐Hinojosa, Alfredo

Mayo Clinic

2025 12th International IEEE/EMBS Conference on Neural Engineering (NER) | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1044-1049

10.1109/ner61569.2025.11589032 Get It

Abstract A049: Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes
Thakkar, Bijal, Wilson, Ashley , Henderson, Jared, Ayers, Amy, Borgschatz, Sara, Harkins, R. Andrew, Lakra, Priya , Cohen, Jonathon B., Russler-Germain, David, Vega, Francisco, Chapman, J., Inghirami, Giorgio, Lossos, Izidore S. , Koff, Jean L., Nze, Chijioke, Martin, Peter, Syrbu, Sergei, Vij, Kiran, Flowers, Christopher R. , Novak, Anne J., Chihara, Dai, Sakata-Yanagimoto, Mamiko, Tobin, Joshua, Green, M, Abe, Yoshiaki , Kizhakeyil, Atish , Feldman, Andrew L. , Henderson, Jared M. , Ayers, Amy , Harkins, R. Andrew , Kaji, Daisuke , Cohen, Jonathon B. , Mou, Eric , Inghirami, Giorgio , Casulo, Carla , Koff, Jean L. , Nze, Chijioke , Syrbu, Sergei , Jaye, David L. , Cerhan, James R. , Novak, Anne J. , Burack, Richard , Sakata‐Yanagimoto, Mamiko , Tobin, Joshua W.D. , Li, Xubin

Mayo Clinic

Blood Cancer Discovery | June 24, 2026 | Volume: 7 | Issue: 3_Supplement | Pages: A049-A049

10.1158/2643-3249.lymphoma26-a049 Get It

Abstract Recent single-cell transcriptomic studies of follicular lymphoma (FL) have revealed heterogeneity among malignant B (MB) cells and selected components of the tumor microenvironment (TME), but have been constrained by relatively small sample sizes and a lack of spatial context. We performed comprehensive cellular profiling and spatial dissection of over five million cells by integrating single-nucleus RNA sequencing (snRNA-seq) from 182 samples (FL, n = 167; control, n = 15) with single-cell spatial transcriptomics (ST) from 386 samples (FL, n = 365; control, n = 21). After stringent quality control, 1,289,073 and 3,968,427 cells from snRNA-seq and ST data, respectively, were analyzed. Unsupervised clustering of snRNA-seq data identified 58 TME cell subtypes. To extend this classification to the ST dataset, we integrated snRNA-seq and ST data by co-embedding them into a shared principal component space, enabling robust batch correction and cell-type label transfer across modalities. Using this supervised annotation framework, ST data recapitulated 54 TME cell subtypes. MB, proliferating MB (MBprolif), and healthy B (HB) cells were classified using sample-level unsupervised clustering in ST. Macrophages exhibited previously uncharacterized heterogeneity in transcriptomic profiles and spatial distribution. We identified CXCL13-expressing macrophage subtypes with high intra- and peri-follicular abundance, termed follicular macrophages (FMs). Non-negative matrix factorization of intrafollicular cell fractions identified five TME archetypes: FM, follicular stroma, two follicular T, and HB archetypes. The FM archetype was enriched for intrafollicular macrophages, including FMs, and showed a significantly higher proportion of grade 3A/3B cases (53.4%) compared to other archetypes (≤16.5%). It was also associated with a higher frequency of high tumor burden requiring treatment initiation rather than a watch-and-wait (WW) approach. Among patients managed by WW, those with the FM archetype showed significantly shorter event-free survival (EFS) compared to those with non-FM archetypes, whereas this association was not observed among treated patients. The percentage of intrafollicular macrophages (IFMP) showed excellent predictive performance for the FM archetype (area under the curve: 0.90). IFMP calculated in a published multiplex spatial protein imaging dataset from an independent cohort of 242 FL patients validated the associations between high IFMP and both pathology grade 3A/3B and shorter EFS in WW patients. Consistently, spatial neighborhood and cell–cell communication analyses revealed co-localization of FMs and MBprolif cells, forming a distinct niche with activated signaling mediated by FM-derived CXCL13, APRIL, and BAFF. Our integrative multi-modal analysis defines previously unrecognized cellular heterogeneity and spatial architecture in FL and highlights macrophage-enriched follicular ecosystems associated with aggressive clinicopathological features, providing a framework for improved biological understanding and patient management. Citation Format: Yoshiaki Abe, Bijal Thakkar, Atish Kizhakeyil, Ashley Wilson, Andrew L. Feldman, Jared Henderson, Amy Ayers, Sara Borgschatz, R. Andrew Harkins, Priya Lakra, Daisuke Kaji, Jonathon B. Cohen, David Russler-Germain, Eric Mou, Francisco Vega, Jennifer Chapman, Giorgio Inghirami, Carla Casulo, Izidore S. Lossos, Jean L. Koff, Chijioke Nze, Peter Martin, Sergei Syrbu, Kiran Vij, David L. Jaye, James R. Cerhan, Christopher R. Flowers, Anne J. Novak, Richard Burack, Dai Chihara, Mamiko Sakata-Yanagimoto, Joshua Tobin, Xubin Li, Michael R. Green. Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr A049.
Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma
Garcia, David M., Lin, Wan‐Hsin , Wickland, Daniel P. , Jessen, Erik , Middlebrooks, Erik H. , Haydu, Lauren E. , Brooks, Mieu , Feathers, Ryan W. , Kinsella, Lindsey , Sereduk, Chris , Rosenfeld, Steven S. , Chaichana, Kaisorn L. , Anastasiadis, Panos Z. , Quiñones‐Hinojosa, Alfredo , Jessen, Erik , Tran, Nhan L , Chaichana, Kaisorn L , Anastasiadis, P Z , Quinones-Hinojosa, Alfredo , Middlebrooks, Erik H , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag139 | PMID 42296327 Get It

Abstract Background Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.
cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas
Brat, Daniel J , Aldape, Kenneth, French, Pim J, Louis, David N, Nasrallah, MacLean P, Reifenberger, G, Reuß, David , Touat, Mehdi, Bent, Martin J van den, Wesseling, Pieter, Figarella-Branger, Dominique, Bent, Martin J. van den , Reifenberger, Guido , Brat, Daniel J. , French, Pim J. , Aldape, Kenneth , French, Pim J , Louis, David N , Nasrallah, MacLean , Reifenberger, Guido , Reuss, David E , Touat, Mehdi , van den Bent, Martin J , Wesseling, Pieter , Figarella-Branger, Dominique , Louis, David N. , Nasrallah, MacLean P. , Wesseling, Pieter , Figarella‐Branger, Dominique

Mayo Clinic

Neuro-Oncology | May 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag108 | PMID 42152226 Get It

Abstract A working group of cIMPACT-NOW evaluated the literature on IDH-mutant gliomas for opportunities to improve pathology-based risk stratification and grading, especially at the interface of CNS WHO grades 2 and 3, since therapeutic decisions depend on risk assessment for clinical management. The group also evaluated newly described IDH-mutant glioma subgroups and considered multidisciplinary aspects of therapeutic decision-making. PDGFRA amplification was associated with highly aggressive clinical behavior of IDH-mutant astrocytomas, consistent with CNS WHO grade 4. Other genetic alterations associated with intermediate risk and most consistent with CNS WHO grade 3 included PIK3 mutations; EGFR alteration; MYCN amplification; and specific retinoblastoma pathway alterations, including CDK4, CDK6, and CCND2 amplification, RB1 homozygous deletion or mutation, and mutation of CDKN2A. DNA methylation signatures of G-CIMP-low or A_IDH_HG were consistent with CNS WHO grade 3 or 4, depending upon other grading criteria. We suggest a mitotic count of ≥3 per 2.4 mm2 could be considered as a CNS WHO grade 3 criterion. Our review did not uncover features to improve the grading of oligodendroglioma, IDH-mutant and 1p/19q-codeleted, although CNS WHO grade 3 tumors with elevated mitotic rates, yet lacking necrosis, microvascular proliferation, CDKN2A/B homozygous deletion, and MRI contrast enhancement, may be associated with extended survival. Implementing evidence-based criteria for risk stratification and grading will improve guidance for clinical decision-making.
Naturalistic Driving Outcomes and Sensorimotor Function in Cognitively Normal Older Adults
Bekena, Semere , Singh, Ramkrishna K. , Zhu, Yiqi, Harrison, Kimystian L. , Williams, Jonathan P., Laurido‐Soto, Osvaldo J., Dickerson, Anne, Carr, David B. , Babulal, Ganesh M., Singh, Ramkrishna K. , Laurido-Soto, Osvaldo , Al‐Hammadi, Noor , Dickerson, Anne D., Babulal, Ganesh M.

Mayo Clinic

Journal of the American Geriatrics Society | March 26, 2026 | Volume: 74 | Issue: 5 | Pages: 1358-1368

10.1111/jgs.70400 | PMID 41884999 Get It

ABSTRACT Background Driving supports independence and quality of life in later life but is vulnerable to age‐related and/or disease‐related decline. While cognitive impairment is a well‐recognized risk for unsafe mobility, the contribution of sensorimotor function is less understood. Methods We studied 374 cognitively normal older adults (Clinical Dementia Rating = 0 at baseline) enrolled in the DRIVES Project. A SensoryMotor Impairment Index (SMI) was constructed from six domains (grip strength, gait speed, reaction time, hearing, vision, olfaction) and categorized as 0, 1, 2, or ≥ 3 impairments. Naturalistic driving was continuously monitored using in‐vehicle GPS dataloggers between 2019 and 2025. Linear mixed‐effects models tested whether longitudinal driving trajectories differed by baseline SMI, adjusting for age, sex, race, education, body mass index, and cognition (Preclinical Alzheimer's Cognitive Composite). Results At baseline, participants with higher SMI burden were older and had lower cognitive scores (both p < 0.01). Over time, greater sensorymotor impairment was associated with faster declines in driving exposure and spatial range. Compared with SMI = 0, participants with SMI ≥ 3 showed steeper reductions in nighttime trips (−0.050 vs. −0.037 trips/month), long‐distance trips (> 20 miles; p < 0.001), and maximum trip distance ( p = 0.009), and greater contraction of driving space (entropy and radius of gyration; p < 0.001). Self‐reported driving behaviors showed that participants with higher SMI drove fewer days per‐week and were more likely to avoid night driving ( p < 0.01). Rates of self‐reported adverse driving events (e.g., crashes or citations) did not differ significantly across SMI groups, consistent with compensatory self‐regulatory behaviors. Conclusion Greater sensorymotor impairment predicts accelerated decline in naturalistic driving among cognitively normal older adults, independent of cognition. A composite SMI may provide a feasible, low‐cost approach to identify older drivers at risk for declining mobility and support timely interventions to prolong safe driving.
The Sport Publication Observational Research Tool (SPORT): An Objective Tool to Score the Methodological Quality of Observational Clinical Sports Medicine Research
Kuhn, Andrew W. , Inclan, Paul M. , Haider, Ameer A. , Christy, Michele, Dunn, Warren, Alberton, Laura A. , Allen, Christina, Anderson, Kyle, Andrews, James, Azar, Fred, Baer, Geoffrey S. , Banffy, Michael B. , Bedi, Asheesh , Brockmeier, Stephen F., Brophy, Robert H. , Bush‐Joseph, Charles A., Carey, James R. , Carter, Thomas, Cohen, Steven, Farrow, Lutul D. , Flanigan, D. Preston, Franklin, Corinna C. , Hame, Sharon L. , Ioannis, Terzidis, Joseph, Sheeba, Kenter, Keith , Koh, Jason R., Krych, Aaron, LeClere, LT Lance, Levy, Bruce, McAllister, David, Morganti, Christina, Musahl, Volker , Nelson, Bradley , Noyes, Frank, Owens, COL Brett D., Pace, Lee, Paulos, Lonnie E., Rodeo, Scott, Safran, Marc, Savoie, Felix H. , Shelbourne, Donald K., Sherman, Seth L. , Singer, Ken, Smith, Matthew, Sonnery-Cottet, Bertrand, Spiker, Andrea M. , Stuart, Michael, Warren, Russell, Wittstein, Jocelyn R. , Wolcott, Michelle L., Wright, Rick, Matava, Matthew J. , Sherman, Seth L. , Kuhn, Andrew W , Dunn, Warren R., Brockmeier, Stephen F. , Brophy, Robert H. , Carey, James, Cohen, Steven B. , Flanigan, David, Krych, Aaron J. , LeClere, Lance E. , Lee, Cassandra Alda , Levy, Bruce, McAllister, David R. , Medvecky, Michael J. , Owens, Brett D. , Pace, J Lee , Redler, Lauren H. , Rodeo, Scott A. , Sonnery‐Cottet, Bertrand

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 6, 2026 | Volume: 14 | Issue: 2 | Pages: No page available

10.1177/23259671251380883 | PMID 41660291 Get It

Background: A critical component of conducting systematic reviews or meta-analyses is assessing the methodological quality and bias of included studies. Several methodological quality assessment tools have been developed; however, these tools may not be relevant to observational sports medicine research, which carries numerous unique nuances and biases. Purpose: To develop the Sport Publication Observational Research Tool (SPORT), which evaluates and scores the methodological quality of observational sports medicine research. Study Design: Consensus statement. Methods: SPORT was developed through a modified Delphi approach involving members from the Herodicus Society and The FORUM. All active members were invited to participate in the process aimed at building consensus on SPORT content and scoring. After finalizing SPORT, a power analysis led to the independent selection of 55 observational clinical sports medicine studies, which were scored twice by 4 reviewers of varying training levels. Interrater and intrarater reliability for SPORT was assessed using intraclass correlation coefficients (ICCs). The distribution and percentiles for total SPORT score across the 55 studies were calculated. SPORT was also compared with the methodological index for non-randomized studies (MINORS), a commonly utilized quality assessment tool. Results: A total of 51 members participated and achieved 100%, 100%, 98.0%, and 98.0% completion rates for rounds 1 through 4, respectively. The final SPORT included 19 subscores related to methodological quality and bias and achieved 94% consensus approval. Mean SPORT completion time was 6 minutes and 19 seconds per study, which varied significantly by reviewer training level. The subscore "peer review" demonstrated unacceptable reliability and was removed. The remaining 18 subscores exhibited ICC ranges of 0.599 to 0.955 for interrater reliability and 0.530 to 0.936 for intrarater reliability. Total SPORT score demonstrated excellent agreement, for interrater (ICC, 0.967) and intrarater reliability (ICC, 0.966). Median SPORT score across the 55 studies was 20.0 and skewed toward lower scores. There was a moderate significant correlation between SPORT and MINORS ( r [53] = 0.575; P < .001). Conclusion: An objective tool to assess the methodologic quality of observational sports medicine research (SPORT) was successfully developed through a modified Delphi approach with numerous content experts in the field. This tool may be useful in assessing the methodological quality of primary observational sports medicine studies included in systematic reviews and meta-analyses.
Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab
Joseph‐Mathurin, Nelly, Chen, Charles D., Hobbs, Diana A, Flores, Shaney, Scott, Jalen, Anand, Sanjana, Franklin, Erin E., Lu, Ruijin , Gordon, Brian A., Jack, Clifford R., Cruchaga, Carlos, Hassenstab, Jason J., Ibanez, Laura, Li, Yan, Wang, Guoqiao, Renton, Alan E., Xiong, Chengjie, Atri, Alireza, Snider, B. Joy, Llibre‐Guerra, Jorge J., Clifford, David B., McDade, DO Eric, Bateman, Randall J., Wang, Qing, Perrin, Richard J., Benzinger, Tammie L.S., team, DIAN‐TU study, Joseph‐Mathurin, Nelly , Jiang, Meng, Flores, Shaney , Franklin, Erin , Gordon, Brian A. , Jack, Clifford R. , Cruchaga, Carlos , Hassenstab, Jason , Ibanez, Laura , Li, Yan, Wang, Guoqiao , Renton, Alan , Xiong, Chengjie , Atri, Alireza , Snider, B. Joy, Llibre‐Guerra, Jorge J. , Clifford, David B. , McDade, Eric , Bateman, Randall J. , Wang, Qing , Perrin, Richard J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | January 10, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107139 Get It

Abstract Background Amyloid related imaging abnormality edema (ARIA‐E) occurs in about 19% of individuals with autosomal dominant Alzheimer disease (ADAD) treated with an anti‐amyloid‐b monoclonal antibody (Salloway et al., 2021). In a previously reported case, ARIA‐E appeared to colocalize with decreases in PiB‐PET uptake (Joseph‐Mathurin, Llibre‐Guerra, et al, 2022), suggesting an association between amyloid‐b (Aβ) removal and ARIA‐E. Here, we compare longitudinal neuroimaging and corresponding neuropathology in an ADAD individual treated with gantenerumab, who experienced multiple ARIA‐E episodes as sulcal effusions that resolved by the end of the four‐year trial. Methods PiB‐PET and MRI were collected pre‐ and post‐randomization (2 and 4 years). The participant consented to brain donation, which was received a year after trial completion. Four tissue samples were taken from the location of the ARIA‐E in the parieto‐occipital left hemibrain as identified by MRI (one block contained the sulcus affected by ARIA‐E; the rest of the coronal section was captured in the remaining three blocks). Area fractions (AFs) of Aβ (10D5 immunohistochemistry (IHC)), tauopathy (PHF1), microglia (Iba1), and astrocytes (GFAP) in one sulcal region of interest (ROI) from each block and PiB‐PET SUVRs of corresponding ROIs were extracted ( n = 4, Figure 1). Additionally, we included PiB‐PET SUVRs corresponding to ARIA‐E findings observed in the right hemisphere at baseline, two‐year, and four‐year visits ( n = 6). Results Overall PiB‐PET uptake increased during the first two years (before ARIA‐E) and decreased during the last two years (including ARIA‐E episodes) (0.03±0.05 vs. ‐0.04±0.04 SUVR/year, p ‐value=0.01, Figure 2). The decrease seemed more pronounced in ARIA‐E ROIs versus normal‐appearing sulcus ROIs (‐0.05±0.04 vs. ‐0.02±0.03 SUVR/year). Lower PiB uptake at last visit appeared associated with lower Aβ AF (estimates=0.03±0.01, p ‐value=0.07). The ARIA‐E ROI had an Aβ AF of 0.009 while normal‐appearing sulcus ROIs had a mean of 0.02+0.003 (Figure 3). AFs for tauopathy, microglia, and astrocytes were within the range of those of normal‐appearing sulcus ROIs, suggesting an Aβ‐specific effect, although unexamined markers may play a role. Conclusions Our preliminary findings indicated that ARIA‐E is associated with longitudinal PiB‐PET decrease and Aβ AF, supporting the link between ARIA‐E, changes in PiB‐PET, and local Aβ removal observed at autopsy. Funding : K01AG080123; U01AG042791; R01AG046179; R01AG053267
Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab
Joseph‐Mathurin, Nelly, Chen, Charles D., Flores, Shaney, Scott, Jalen , Anand, Sanjana, Franklin, Erin E., Lu, Ruijin , Gordon, Brian A., Jack, C. R., Cruchaga, Carlos C, Hassenstab, Jason J., Ibanez, Laura, Li, Yan, Wang, Guoqiao, Renton, Alan E., Xiong, Chengjie, Atri, A., Snider, B. Joy, Clifford, David B., Bateman, Randall J., Wang, Q., Perrin, Richard J., Benzinger, Tammie L.S., Jack, Clifford R. , Jack, Clifford R , Joseph‐Mathurin, Nelly , Hobbs, Diana A. , Jiang, Meng, Flores, Shaney , Franklin, Erin , Gordon, Brian A. , Cruchaga, Carlos , Ibanez, Laura , Wang, Guoqiao , Renton, Alan , Xiong, Chengjie , Snider, B. Joy, Llibre‐Guerra, Jorge J. , Clifford, David B. , McDade, Eric , Bateman, Randall J. , Perrin, Richard J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110062 Get It

Abstract Background Amyloid related imaging abnormality edema (ARIA‐E) occurs in about 19% of individuals with autosomal dominant Alzheimer disease (ADAD) treated with an anti‐amyloid‐b monoclonal antibody (Salloway et al., 2021). In a previously reported case, ARIA‐E appeared to colocalize with decreases in PiB‐PET uptake (Joseph‐Mathurin, Llibre‐Guerra, et al, 2022), suggesting an association between amyloid‐b (Aβ) removal and ARIA‐E. Here, we compare longitudinal neuroimaging and corresponding neuropathology in an ADAD individual treated with gantenerumab, who experienced multiple ARIA‐E episodes as sulcal effusions that resolved by the end of the four‐year trial. Methods PiB‐PET and MRI were collected pre‐ and post‐randomization (2 and 4 years). The participant consented to brain donation, which was received a year after trial completion. Four tissue samples were taken from the location of the ARIA‐E in the parieto‐occipital left hemibrain as identified by MRI (one block contained the sulcus affected by ARIA‐E; the rest of the coronal section was captured in the remaining three blocks). Area fractions (AFs) of Aβ (10D5 immunohistochemistry (IHC)), tauopathy (PHF1), microglia (Iba1), and astrocytes (GFAP) in one sulcal region of interest (ROI) from each block and PiB‐PET SUVRs of corresponding ROIs were extracted ( n = 4, Figure 1). Additionally, we included PiB‐PET SUVRs corresponding to ARIA‐E findings observed in the right hemisphere at baseline, two‐year, and four‐year visits ( n = 6). Results Overall PiB‐PET uptake increased during the first two years (before ARIA‐E) and decreased during the last two years (including ARIA‐E episodes) (0.03±0.05 vs. ‐0.04±0.04 SUVR/year, p ‐value=0.01, Figure 2). The decrease seemed more pronounced in ARIA‐E ROIs versus normal‐appearing sulcus ROIs (‐0.05±0.04 vs. ‐0.02±0.03 SUVR/year). Lower PiB uptake at last visit appeared associated with lower Aβ AF (estimates=0.03±0.01, p ‐value=0.07). The ARIA‐E ROI had an Aβ AF of 0.009 while normal‐appearing sulcus ROIs had a mean of 0.02+0.003 (Figure 3). AFs for tauopathy, microglia, and astrocytes were within the range of those of normal‐appearing sulcus ROIs, suggesting an Aβ‐specific effect, although unexamined markers may play a role. Conclusions Our preliminary findings indicated that ARIA‐E is associated with longitudinal PiB‐PET decrease and Aβ AF, supporting the link between ARIA‐E, changes in PiB‐PET, and local Aβ removal observed at autopsy. Funding : K01AG080123; U01AG042791; R01AG046179; R01AG053267